Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis

BACKGROUND: Due to the increasing number of trials with immune checkpoint inhibitors (ICIs) in the first‐line therapy of non‐small cell lung cancer (NSCLC) patients, we performed a systematic review and meta‐analyses to investigate the difference between anti PD‐1 and PD‐L1 antibodies, used alone or...

Descripción completa

Detalles Bibliográficos
Autores principales: Brito, Angelo Borsarelli Carvalho, Camandaroba, Marcos Pedro Guedes, de Lima, Vladmir Cláudio Cordeiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017262/
https://www.ncbi.nlm.nih.gov/pubmed/33586297
http://dx.doi.org/10.1111/1759-7714.13867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017262/
https://www.ncbi.nlm.nih.gov/pubmed/33586297
http://dx.doi.org/10.1111/1759-7714.13867

Ejemplares similares